FDA Approves Rubraca for Maintenance Ovarian Cancer Treatment

April 6, 2018 8:05 pm

The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the … Read more

Participation In Clinical Trials May Eliminate Ovarian Cancer Survival Disparities

April 4, 2018 5:22 pm

Improving the diversity of enrollment in clinical trials may improve health disparities among women with ovarian cancer, according to study results presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

“Our study is evidence that no one … Read more

SGO 2018: Immunotherapy/PARP Inhibitor Combination Produces Remissions in Ovarian Cancer

April 2, 2018 5:19 pm

A combination of the immunotherapy pembrolizumab (Keytruda) and the DNA repair–blocking agent niraparib (Zejula) can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers … Read more

Four Individuals Named Ovarian Cancer Heroes at Inaugural Event

March 30, 2018 10:12 pm

Driving research and awareness by working together are ways in which the word cure might one day be heard in the ovarian cancer community. Members of the tight knit “teal army” gathered last night for the inaugural Ovarian Cancer Heroes … Read more

SGO 2018: Putting PARP Inhibitor Perspectives Into Practice

March 28, 2018 9:28 pm

Achieving consensus on which poly (ADP-ribose) polymerase (PARP) inhibitor to use and when during management of ovarian cancer proved challenging Sunday for 4 oncologists who took attendees through a lively discussion of applying current standards from professional societies to everyday … Read more

SGO 2018: A Vaccine Shows Promise Against Ovarian Cancer

March 26, 2018 9:11 pm

A vaccine derived from a patient’s tumor cells, which enhances T-cell targeting of cancer cells, has shown promise against ovarian cancer.

This outcome of a phase 1 clinical trial was reported at the Society of Gynecologic Oncology’s 2018 Annual Meeting … Read more

PapSEEK: Potential Screening Test for Gynecologic Cancers

March 23, 2018 7:29 pm

A sample obtained from routine Papanicolaou (Pap) tests used for cervical cancer screening can be subjected to a multiplex panel test, dubbed PapSEEK, to determine whether the sample is positive for endometrial or ovarian cancer, two gynecologic cancers for which … Read more

Vulnerable Populations Lack Sufficient Clinical Trial Information

March 21, 2018 2:30 pm

Despite showing an interest in clinical trials and biobanking, underserved populations appear to be unclear on how to learn about them, while community physicians reported lacking appropriate information to give them, according to data to be presented at the American … Read more

U.S. To Cover Advanced Genomic Testing For Medicare Cancer Patients

March 19, 2018 7:17 pm

The U.S. government said on Friday it will pay for certain genetic tests for Medicare-eligible patients with advanced cancer, in a bid to help match patients with the drugs most likely to provide benefit.

The Centers for Medicare & Medicaid … Read more

Could New Approach Stave Off Ovarian Cancer? Study May Tell

March 16, 2018 7:08 pm

Anna Hargrove learned she carries a genetic mutation that predisposes women toward breast and ovarian cancer at 27, which was no surprise given her family history.

Hargrove, cautious by nature, did what a lot of women with the mutation do: … Read more

Liquid Biopsy Tests in People with Cancer: An Expert Review

March 14, 2018 7:03 pm

Use of tests that assess genomic variants in circulating tumor DNA (ctDNA) is on the rise. A new joint review from the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) provides an assessment of evidence … Read more

FDA Approves 23andMe Cancer Test For BRCA Genes

March 12, 2018 8:33 pm

The home DNA testing company 23andMe has received approval from the US Food and Drug Administration (FDA) to test for three genetic mutations in two genes that you have probably heard of if you know who Angelina Jolie is, BRCA1 … Read more

Why Many Patients Join Phase 1 Clinical Trials

March 7, 2018 6:12 am

“Fighting my cancer as much as possible” is why many patients participate in early stage clinical trials, according to research presented at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris, France.

“The importance of early stage trials is … Read more

Hidden Burdens: The Effects of an Ovarian Cancer Diagnosis

February 23, 2018 6:51 pm

By: Kristie Kahl

After a cancer diagnosis and treatment, one may question when they will actually start to feel “normal” again, whatever that may be. The Ovarian Cancer Prognosis and Lifestyle (OPAL) study set out to help women with ovarian … Read more

Doctors Said Immunotherapy Would Not Cure Her Cancer. They Were Wrong.

February 21, 2018 7:16 pm

No one expected the four young women to live much longer. They had an extremely rare, aggressive and fatal form of ovarian cancer. There was no standard treatment.

The women, strangers to one another living in different countries, asked their … Read more

Ovarian Cancer: How Your Father’s Genes Can Affect Your Risk

February 19, 2018 12:01 am

Scientists studying ovarian cancer have revealed a new genetic mutation that increases a woman’s risk of ovarian cancer — and it can be passed to her by her father.

Recently, Medical News Today covered a study that looked into whether … Read more

A Cancer Researcher Takes Cancer Personally

February 16, 2018 11:59 pm

By: Susan Gubar

Ongoing breakthroughs in cancer care involve personalized medicine, we are often informed. Because every malignancy is unique in terms of its genetics and genomics, one size (or protocol) cannot fit all.

A diagnosis of multiple myeloma, cancer … Read more

‘No’ to Ovarian Cancer Screening: Harms Outweigh Benefits

February 14, 2018 8:49 pm

Women should not undergo screening for ovarian cancer if they do not have signs or symptoms of the disease, as it does not improve survival but may expose women unnecessarily to surgical complications. This is the final guidance from the … Read more

Screening Beyond Those With Cancer History May Be More Effective

February 12, 2018 10:32 pm

As genetic testing becomes more accessible with advanced technology and decreased costs, population-based testing for breast and ovarian cancer may be more cost effective in the long run, according to study results published in Journal of the National Cancer InstituteRead more